177Lu-PSMA-617 Radioligand Therapy in Patient With Prostate Cancer Sciatic Nerve Metastasis
Patients with metastatic castration-resistant prostate cancer usually have lymph nodes and bone metastasis. We present a rare case of a 51-year-old patient with metastatic castration-resistant prostate cancer who complained of left truncated sciatica and diffuse bone pain and who was referred for 177 Lu-prostate-specific membrane antigen (PSMA) screening. Pretreatment 68 Ga-PSMA showed left sciatic nerve and multiple bone uptake. Patient underwent stereotactic radiotherapy on the sciatic nerve metastasis (30 Gy in 6 fractions of 5 Gy) before 7.4 GBq of 177 Lu-PSMA infusions. Left truncated sciatica disappeared after stereotactic radiotherapy. No additional toxicity was added to the sciatic nerve from 177 Lu-PSMA after stereotactic radiotherapy.
Authors
- S. Thureau (ORCID: https://orcid.org/0000-0001-5772-2336)
- Agathe Edet‐Sanson
- Marine Cabourg
- David Tonnelet (ORCID: https://orcid.org/0000-0002-8609-0611)
- Laetitia Augusto
Institutions
- Clinique Saint-Joseph (BE)
- Centre Hospitalier Universitaire de Rouen (FR)
Publication Details
- Journal
- Clinical Nuclear Medicine
- Published
- 2024-10-14
- DOI
- https://doi.org/10.1097/rlu.0000000000005503
- Citations
- 1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.42